Dr. William Bensinger, myeloma expert from the Seattle Cancer Care Alliance, shares results from a recent study reported at ASH 2012 using an old drug, Amifostine, in a new way to increase treatment response for multiple myeloma patients. As the lead investigator for this work, he explains the positive outcome testing a treatment regimen using higher doses of cancer-fighting agents while mitigating toxicity with this cytoprotective agent.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…